Suppr超能文献

霉酚酸酯作为肝移植单一疗法的有效性和安全性。

Effectiveness and safety of mycophenolate mofetil as monotherapy in liver transplantation.

作者信息

Moreno J M, Rubio E, Gómez A, Lopez-Monclus J, Herreros A, Revilla J, Navarrete E, Sánchez Turrión V, Jimenez M, Cuervas-Mons V

机构信息

Department of Medicine, Hospital Universitario Puerta de Hierro, Universidad Autónoma, Madrid, Spain.

出版信息

Transplant Proc. 2003 Aug;35(5):1874-6. doi: 10.1016/s0041-1345(03)00643-2.

Abstract

INTRODUCTION

Calcineurin inhibitors (CIs) cause substantial long-term morbidity and mortality among orthotopic liver transplantation (OLT) patients. Our aim was to evaluate the effectiveness and safety of mycophenolate mofetil (MMF) among OLT patients with CI-related side effects.

PATIENTS

Thirty three adult patients, including 29 men and 4 women of mean age 57 years, underwent OLT between 1986 and 2000 under treatment with CIs (28 cyclosporine and five tacrolimus). Mean follow-up after OLT was 59 months. Adverse effects were renal dysfunction in 26, hypertension in 23, and neurotoxicity in two. MMF was added gradually while simultaneously reducing the dosage of CI.

RESULTS

After a mean 15-months follow-up of MMF treatment, CIs had been withdrawn in 28 patients (85%). The mean time from the initiation of MMF and CI withdrawal was 5 months. During the first year of follow-up chronic renal dysfunction improved in 16 of 26 patients (61.6%) accompanied by a decreased serum creatinine and urea and an increase in creatinine clearance. Among 13/23 (56.5%) hypertensive patients, there was a significant decrease in blood pressure or the number of antihypertensive drugs (P<.05). One patient with neurotoxicity improved. Twenty-two patients (66%) displayed adverse events: five rejections (15%) including four acute episodes, controlled by CI re-introduction, and one chronic reaction. The most frequent adverse effects were herpes simplex infection in 10 patients (30%), asthenia in nine (27%), diarrhea in five (15%) and thrombocytopenia in four (12%). Nevertheless, only six patients (19%) required MMF dose reduction, namely, three patients with GI intolerance, two with repeated VHS infections, and one with anemia.

CONCLUSIONS

MMF monotherapy improves renal function and blood pressure levels in more than 50% of patients with chronic renal impairment and hypertension after OLT. Many of the side effects of MMF were mild; it was safe accompanied by a low incidence of rejection reactions.

摘要

引言

钙调神经磷酸酶抑制剂(CIs)在原位肝移植(OLT)患者中会导致严重的长期发病和死亡。我们的目的是评估霉酚酸酯(MMF)在有CI相关副作用的OLT患者中的有效性和安全性。

患者

33例成年患者,包括29名男性和4名女性,平均年龄57岁,于1986年至2000年间在接受CIs治疗(28例环孢素和5例他克莫司)的情况下接受了OLT手术。OLT术后平均随访59个月。不良反应包括26例肾功能不全、23例高血压和2例神经毒性。在逐渐减少CI剂量的同时逐渐加用MMF。

结果

在MMF治疗平均随访15个月后,28例患者(85%)停用了CIs。从开始使用MMF到停用CI的平均时间为5个月。在随访的第一年,26例慢性肾功能不全患者中有16例(61.6%)病情改善,血清肌酐和尿素水平降低,肌酐清除率升高。在13/23例(56.5%)高血压患者中,血压或抗高血压药物数量显著降低(P<0.05)。1例神经毒性患者病情改善。22例患者(66%)出现不良事件:5例排斥反应(15%),包括4例急性发作,通过重新使用CI得到控制,1例慢性反应。最常见的不良反应是10例患者(30%)出现单纯疱疹感染,9例(27%)出现乏力,5例(15%)出现腹泻,4例(12%)出现血小板减少。然而,只有6例患者(19%)需要减少MMF剂量,即3例胃肠道不耐受患者、2例反复出现VHS感染患者和1例贫血患者。

结论

MMF单药治疗可使超过半数的OLT术后慢性肾功能损害和高血压患者的肾功能和血压水平得到改善。MMF的许多副作用较轻;其安全性良好,排斥反应发生率较低。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验